ENTITY

Zai Lab (9688 HK)

22
Analysis
Health CareChina
Zai Lab Limited operates as a biopharmaceutical company. The Company researches and develops therapeutic technology for antibody-based oncology, autoimmune, and infectious diseases treatments. Zai Lab also manufactures drugs in the form of capsules, injections, and liquids. Zai Lab serves patients worldwide.
more
bearishZai Lab
05 Sep 2024 01:21

Zai Lab (9688 HK): Vyvgart Is Not the De-Risking Tool; Future Is Still Uncertain

​Zai Lab's Vyvgart revenue sees significant growth, but challenges remain with decelerating Zejula revenue and lower gross profit margins due to in...

Logo
421 Views
Share
bearishZai Lab
02 Jun 2024 15:09

China Healthcare Weekly (Jun.2) - Innovent's Trouble, Hengrui's “smart Deal”, Zai Lab’s Pain Point

​Innovent's PD-1 growth face bottleneck, with uncertainty in 24H2 growth; Hengrui-Hercules deal a "smart" asset spin-off; Zai Lab has positive...

Logo
306 Views
Share
14 Dec 2022 09:38

China ADRs Delisting - Friday Could Be Judgment Day for over US$800bn Mcap of Stocks

PCAOB officials concluded their Hong Kong visit last month and PCAOB is due to announce its annual judgment on whether it had adequate access to US...

Logo
905 Views
Share
10 Sep 2024 05:49

Alibaba (9988 HK/BABA) Dual Primary Listing: Are We There Yet?

Alibaba will be in included in Southbound Stock Connect from the open of trading today. Volumes should be higher than usual as mainland investors...

Logo
1.8k Views
Share
27 Oct 2024 07:30

APAC Healthcare Weekly (Oct 27)- Samsung Biologics, Celltrion, Astellas, Otsuka, Legend, and Zai Lab

Samsung Biologics secures largest ever contract, Celltrion announced KRW100B buyback, Astellas Pharma got label expansion approval for Vyloy,...

Logo
452 Views
Share
x